137 related articles for article (PubMed ID: 35575415)
41. Aggressive prolactinoma (Review).
Valea A; Sandru F; Petca A; Dumitrascu MC; Carsote M; Petca RC; Ghemigian A
Exp Ther Med; 2022 Jan; 23(1):74. PubMed ID: 34934445
[TBL] [Abstract][Full Text] [Related]
42. The trophic effects of oestrogen on male rat anterior pituitary lactotrophs.
Nolan LA; Levy A
J Neuroendocrinol; 2009 May; 21(5):457-64. PubMed ID: 19302189
[TBL] [Abstract][Full Text] [Related]
43. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
44. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
45. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
46. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
Botelho CH; Magalhães AV; Mello PA; Schmitt FC; Casulari LA
Arq Neuropsiquiatr; 2006 Mar; 64(1):60-6. PubMed ID: 16622555
[TBL] [Abstract][Full Text] [Related]
47. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
[TBL] [Abstract][Full Text] [Related]
48. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report.
Kovacs K; Stefaneanu L; Horvath E; Buchfelder M; Fahlbusch R; Becker W
J Neurosurg; 1995 May; 82(5):886-90. PubMed ID: 7714616
[TBL] [Abstract][Full Text] [Related]
49. Oophorectomy improves pituitary activin inhibitory function preventing lactotroph hyperplasia development.
Peña-Zanoni M; Faraoni EY; Abeledo-Machado A; Perez PA; Marcial López CA; Camilletti MA; Gutierrez S; Rulli SB; Diaz-Torga G
Endocr Relat Cancer; 2022 May; 29(6):359-373. PubMed ID: 35324456
[TBL] [Abstract][Full Text] [Related]
50. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
Maïza JC; Caron P
Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
[TBL] [Abstract][Full Text] [Related]
51. Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
Demarchi G; Perrone S; Esper Romero G; De Bonis C; Casasco JP; Sevlever G; Berner SI; Cristina C
Front Endocrinol (Lausanne); 2022; 13():870172. PubMed ID: 35928898
[TBL] [Abstract][Full Text] [Related]
52. A single- center experience of prolactin-producing pituitary adenomas without hyperprolactinemia: Its incidence and clinical management.
Ogawa Y; Tominaga T
Clin Neurol Neurosurg; 2020 Nov; 198():106123. PubMed ID: 32818756
[TBL] [Abstract][Full Text] [Related]
53. A thyrotropin-secreting macroadenoma with positive growth hormone and prolactin immunostaining: A case report and literature review.
Kuzu F; Bayraktaroğlu T; Zor F; G N BD; Salihoğlu YS; Kalaycı M
Niger J Clin Pract; 2015; 18(5):693-7. PubMed ID: 26096253
[TBL] [Abstract][Full Text] [Related]
54. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
55. Aggressive pituitary tumours and pituitary carcinomas.
Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
[TBL] [Abstract][Full Text] [Related]
56. Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience.
Lasolle H; Teulade M; Lapras V; Vasiljevic A; Borson-Chazot F; Jouanneau E; Raverot G
Ann Endocrinol (Paris); 2022 Feb; 83(1):1-8. PubMed ID: 34871604
[TBL] [Abstract][Full Text] [Related]
57. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
58. [New aspects of tumor pathology of the pituitary].
Saeger W
Pathologe; 2015 May; 36(3):293-300. PubMed ID: 25947224
[TBL] [Abstract][Full Text] [Related]
59. ACTH-secreting Crooke cell carcinoma of the pituitary.
Kovács GL; Góth M; Rotondo F; Scheithauer BW; Carlsen E; Saadia A; Hubina E; Kovács L; Szabolcs I; Nagy P; Czirják S; Hanzély Z; Kovács K; Horváth É; Korbonits M
Eur J Clin Invest; 2013 Jan; 43(1):20-6. PubMed ID: 23134557
[TBL] [Abstract][Full Text] [Related]
60. Synchronous pituitary adenoma and pituicytoma.
Neidert MC; Leske H; Burkhardt JK; Kollias SS; Capper D; Schrimpf D; Regli L; Rushing EJ
Hum Pathol; 2016 Jan; 47(1):138-43. PubMed ID: 26476569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
